COMMUNIQUÉS West-GlobeNewswire

NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to [...]
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
04/09/2025
WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the [...]
Algernon Pharmaceuticals Announces Name Change to Algernon Health
04/09/2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is [...]
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
04/09/2025
Development Candidate Targeting IRAK4 Now Progressing Toward Clinical Development WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical [...]
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
04/09/2025
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared [...]
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
04/09/2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical [...]
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
04/09/2025
CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on [...]
GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
The Company is available for one-on-one meetings at the H.C. Wainwright Conference September 8-10, 2025 in New York City Phase 1 trial evaluating GTBP-3650 for the treatment of relapsed or refractory (r/r) CD33 [...]
Immunocore to present at upcoming investor conferences
04/09/2025
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company [...]
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today [...]
ALK expands the Executive Leadership Team to include key commercial regions
04/09/2025
ALK (ALKB:DC / OMX: ALK B) today announced the decision to elevate its key commercial regions into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s strategy, Allergy+ . Effective as of 1 [...]
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
04/09/2025
Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual Targeted [...]
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
04/09/2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI- [...]
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
04/09/2025
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of [...]
Lygos Clinic Launches VIP All-Inclusive Dental Tourism Packages for International Patients
04/09/2025
ISTANBUL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, a leading dental center in Istanbul, has officially launched its new VIP all-inclusive dental tourism packages , designed to meet the rising global demand for [...]
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
04/09/2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s [...]
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
04/09/2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO [...]
Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD)
04/09/2025
Susvimo is under review with the EMA and once approved will be the first continuous delivery treatment for nAMD, affecting 1,7 million in the European Union 1 New seven-year data from the LADDER study show Contivue with [...]
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
04/09/2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, [...]

Pages